How much is Oncolytics Biotech stock worth?
One share of ONC stock can currently be purchased for approximately C$2.36. How much money does Oncolytics Biotech make? Oncolytics Biotech has a market capitalization of C$129.86 million.
How do I buy ONC shares?
Shares of ONC and other Canadian stocks can be purchased through an online brokerage account.
What are Wall Street's price targets for Oncolytics Biotech's stock?
3 Wall Street analysts have issued 12-month price targets for Oncolytics Biotech's stock. Their forecasts range from C$6.00 to C$6.00. On average, they expect Oncolytics Biotech's share price to reach C$6.00 in the next year. This suggests a possible upside of 154.2% from the stock's current price.
Who is the CEO of oncosec Medical Inc?
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Daniel O'Connor has resigned and that Brian Leuthner, formerly Chief Operating Officer, has been appointed Interim Chief Executive Officer, effective June 25, 2021. Mr. O' Connor is also stepping down from his seat on the Board of Directors.
Oncoceutics Comparisons
Oncoceutics Signals
dipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
What is the ONC?
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
When is Oncolytics earnings call 2021?
(NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer. The data will be featured in an upcoming electronic poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 – 8, 2021.
When is the Canaccord Genuity conference 2021?
NEW YORK, NY / ACCESSWIRE / May 7, 2021 / Oncolytics Biotech, Inc. (NASDAQ:ONCY) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 7, 2021 at 12:10 PM Eastern Time.
How much is Oncocyte's net loss for the first quarter of 2021?
(NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference, which is taking place virtually from August 10-12, 2021. Presentation details are listed below.
What is the name of the CDX for cancer?
Cash used in operations was approximately $9.8 million for the first quarter of 2021.
How much was the operating loss in 2021?
Amgen and QIAGEN originally initiated their collaboration to develop a tissue-based CDx for investigational cancer treatment with AMG 510, now named LUMAKRAS, which is the first KRAS G12C inhibitor to advance to the clinic targeting the KRAS G12C oncogene, one of the genes most frequently mutated in human cancers.
Who owns Razor Genomics?
Operating losses, as reported, for the first quarter of 2021 were $11.4 million, an increase of $3.0 million from $8.4 million as compared to the first quarter of 2020. Operating losses, on an adjusted basis, were $8.6 million, an increase of $1.2 million from $7.4 million as compared to the first quarter of 2020.
How much will research and development cost in 2021?
In February 2021, Oncocyte completed the acquisition of the remaining equity interests in Razor Genomics and paid the $10 million cash portion to the selling shareholders, so Oncocyte now owns all of the outstanding common stock of Razor and will consolidate Razor as of that date.
About
Research and development expenses for the first quarter of 2021 were $3.4 million as compared to $2.2 million for the same period in 2020, an increase of $1.2 million, primarily due to increased investment in DetermaIO, personnel and related expenses.
Highlights
Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer.
M&A Details
View contacts for Oncoceutics to access new leads and connect with decision-makers.
What is Oncosec Medical?
Oncoceutics was acquired by Chimerix for $78M on Jan 8, 2021. This deal was done in Cash & Stock.
What is Oncosec IL-12?
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral cancer immunotherapies, today announced it will sponsor a key opinion leader (KOL) webinar to be held by LifeSci Advisors discussing the anti-PD-1 checkpoint refractory metastatic melanoma landscape and the impact of the results from ILLUMINATE-301 on Wednesday, March 31, 2021 at 12:00 p.m. ET.
Who is the Vice President of Oncosec?
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced that it will be presenting encore interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVO™ (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), in combination with KEYTRUDA® (pembrolizumab) in rigorously defined anti-PD1 checkpoint resistant metastatic melanoma patients at the 10th World Congress of Melanoma. This is an encore presentation of data presented at The Society for Immunotherapy of Cancer's (SITC) 2020 Annual Meeting. Presenters will also discuss the therapeutic potential of OncoSec's DNA medicines platform to elicit robust anti-tumor immunity via intratumoral gene electrotransfer of TAVO plus CXCL9.
What is CE mark?
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), today announced the appointment of Jeffrey Silverman as Vice President of Product Engineering, effective June 14, 2021. Mr. Silverman, an engineering management veteran, brings to OncoSec extensive global industry experience spanning more than 20 years, in the development, manufacturing and scale up of Medical Devices including electroporation and gene delivery equipment for the delivery of DNA drugs in support of cancer an
When will Onco publish its report?
The CE mark certification augments the Notified Body certification to the International Organization for Standardization's (ISO) 13485 standard for the design, development, manufacture and distribution of electroporation devices, which is renewed annually, subject to a successful audit.
What is ONCO AB?
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, will publish its report for the first quarter 2021 on May 26.
What is Oncopeptides AB?
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the report for the first quarter 2021.
Is Oncopeptides AB a phase 2 study?
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that three abstracts with data on PEPAXTO® (melphalan flufenamide, also known as melflufen) in relapsed refractory multiple myeloma, have been accepted by the 2021 American Society of Clinical Oncology, ASCO, and have now been published online. The clinical data presentations include updates on Oncopeptides' ANCHOR and LIGHTHOUSE studies as well as a pooled analysis of the O-12-M1 and HORIZON studies in patients who have been exposed to or become refractory to prior alkylators.
About Oncolytics Biotech
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the Company has completed patient enrollment in the phase 2 PORT study. The PORT study is an open-label, randomized, cross-over study which compares safety, tolerability and efficacy of peripheral or central intravenous administration of melflufen (INN melphalan flufenamide) in combination with dexamethasone in relapsed refractory multiple myeloma. Oncopeptides expects topline data in Q3 2021.
Headlines
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies.
Oncolytics Biotech (TSE:ONC) Frequently Asked Questions
Is Oncolytics Biotech's GOBLET Study Making Headway in the Fight Against Pancreatic and Colorectal Tumors?
Is it Great to Invest in ON Semiconductor Corp. (ON)?
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 hold rating and 1 buy rating for the stock.
The Zacks Analyst Blog Highlights: Apple Inc., Tesla Inc. , Advanced Micro Devices Inc., Texas Instruments Inc. and ON Semiconductor Corp
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded here. A return of -0.72% was recorded by its Investor Class: ARTMX, -0.68% by its Advisor Class: APDMX, and -0.66% by its Institutional Class: APHMX, in the fourth […]
Top 5 Nasdaq Composite Stocks Amid Index's YTD Bloodbath
Apple Inc., Tesla Inc. , Advanced Micro Devices Inc., Texas Instruments Inc. and ON Semiconductor Corp. are highlighted in this Analyst Blog.
4 Top-Ranked Semiconductor Stocks to Buy Amid Industry Growth
We have narrowed our search to five Nasdaq Composite listed U.S. corporate behemoths that have a robust business model. These are: AAPL, TXN, AMD, ON and TSLA.
Best Momentum Stocks to Buy for February 10th
Here we discuss four semiconductor stocks, namely MaxLinear (MXL), ON Semiconductor (ON), Advanced Micro Devices (AMD) and Monolithic Power Systems (MPWR), which are well poised to benefit from strong chip demand.
New Strong Buy Stocks for February 10th
ON, SAIA, and PAGP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 10, 2022
ON Semiconductor Corporation's (NASDAQ:ON) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
DLA, PAGP, KFRC, ON and SAIA have been added to the Zacks Rank #1 (Strong Buy) List on February 10, 2022.
